Page last updated: 2024-12-05

saccharin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Saccharin is an artificial sweetener that is about 300 times sweeter than sugar. It is synthesized by reacting toluene with chlorosulfonic acid to form o-toluenesulfonamide, which is then oxidized to saccharin. Saccharin is used as a sugar substitute in food and beverages, as well as in pharmaceuticals and personal care products. It has been studied extensively for its potential health effects, including its possible role in cancer. However, the evidence for a link between saccharin and cancer is inconclusive. Saccharin is still widely used as a sweetener, although some people prefer to avoid it due to its potential health risks.'

Saccharin: Flavoring agent and non-nutritive sweetener. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5143
CHEMBL ID310671
CHEBI ID32111
SCHEMBL ID3816
MeSH IDM0019327

Synonyms (249)

Synonym
1,1-dioxo-1,2-benzisothiazol-3(2h)-one
1,1-dioxo-1,2-dihydro-benzo[d]isothiazol-3-one
e954
ins-954(i)
ins no.954(i)
e-954(i)
saccharinum
chebi:32111 ,
o-benzoic sulfimide
3-hydroxybenzisothiazole s,s-dioxide
o-benzosulfimide
benzosulfimide
1,2-dihydro-2-ketobenzisosulfonazole
anhydro-o-sulfaminebenzoic acid
nsc5349
2,3-dihydro-3-oxobenzisosulfonazole
o-sulfobenzoic acid imide
saccharin, insoluble
saccharine
saccharol
hermesetas
wln: t56 bswmvj
o-benzoyl sulfimide
gluside
o-sulfobenzimide
saccharinose
glucid
saccharinol
benzoic sulfimide
garantose
saccharimide
nsc-5349
550 saccharine
saccharin acid
3-benzisothiazolinone 1,1-dioxide
1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[d]isothiazol-3-one
DIVK1C_000164
KBIO1_000164
SPECTRUM_000213
BSPBIO_003029
1,2-benzisothiazol-3(2h)-one, 1,1-dioxide
1,1-dioxo-1,2-benzothiazol-3-one
nsc5731
sykose
1, 2-benzothiazol-3(2h)-one 1,1-dioxide sodium salt
1, 2-benzisothiazol-3(2h)-one, 1,1-dioxide, sodium salt
sodium 1,2 benzisothiazolin-3-one 1,1-dioxide
1,2-benzisothiazol-3(2h)-one 1,1-dioxide
sweeta
1, 2-benzisothiazolin-3-one, 1,1-dioxide, sodium salt
IDI1_000164
inchi=1/c7h5no3s/c9-7-5-3-1-2-4-6(5)12(10,11)8-7/h1-4h,(h,8,9
sucrette
zaharina
nsc 5349
2,3-dihydro-3-oxobenzisosulphonazole
1,2-benzisothiazolin-3-one 1,1-dioxide
sacarina
nsc 5731
rcra waste no. u202
ai3-38107
sucre edulcor
sulfobenzimide, o-
benzosulfinide
benzoic acid sulfimide
kandiset
saccharin insoluble
o-benzosulphimide
1,2-benzisothiazolin-3-one, 1,1-dioxide
sacharin [czech]
benzo-2-sulphimide
rcra waste number u202
benzosulfimide, o-
benzoic sulphimide
o-benzoic sulphimide
o-benzoyl sulphimide
3-hydroxybenzisothiazole-s,s-dioxide
hsdb 669
saccharin [usan]
benzoylsulfonic imide
natreen
1,2-dihydro-2-ketobenzisosulphonazole
saccharin (only persons who manufacture are subject, no supplier notification)
2-sulphobenzoic imide
insoluble saccharin
einecs 201-321-0
1,1-dioxide-1,2-benzisothiazolin-3-one
benzosulphimide
saccharin
81-07-2
saxin
D01085
sweeta (tn)
saccharin (jp17/nf)
saccharin, >=99%
saccharin, >=98%
NCGC00094918-03
LSA ,
NCGC00094918-01
NCGC00094918-02
KBIO3_002529
KBIOGR_000838
KBIO2_005829
KBIO2_003261
KBIO2_000693
KBIOSS_000693
SPECTRUM4_000449
NCIOPEN2_005180
NINDS_000164
SPECTRUM2_001432
SPBIO_001564
SPECTRUM3_001475
NCIOPEN2_005140
SPECTRUM1501171
SPECTRUM5_001181
NCGC00094918-04
dtxsid5021251 ,
NCGC00094918-05
HMS2092J09
03AC8EC2-D02A-464C-A7C3-7CABD643CC1E
B0004
chembl310671 ,
bdbm29278
HMS500I06
HMS1921N03
1,2-benzothiazol-3(2h)-one 1,1-dioxide
STK803263
AKOS000120481
BBL015343
NCGC00094918-06
fst467xs7d ,
ec 201-321-0
saccharin [nf]
sacharin
unii-fst467xs7d
2-sulfobenzoic acid imide
2,3-dihydroxy-1,2-benzisothiazol-3-one-1,1-dioxide
dtxcid401251
NCGC00256329-01
cas-81-07-2
tox21_302950
tox21_201880
NCGC00259429-01
nsc-757878
nsc757878
pharmakon1600-01501171
tox21_111358
tolunene-2-sulfonamide
CCG-39011
FT-0674493
FT-0674494
saccharin-13c6
2Q38
S4819
AKOS017272711
gtpl5432
2,3-dihydro-1$l^{6},2-benzothiazole-1,1,3-trione
saccharin [hsdb]
saccharin [mi]
saccharin [iarc]
saccharin [mart.]
saccharin [jan]
saccharin [who-dd]
saccharin [inci]
saccharin [vandf]
saccharin [fcc]
saccharinum [hpus]
saccharin [ii]
saccharin [usp-rs]
saccharin [ep monograph]
AB00052233-04
SCHEMBL3816
tox21_111358_1
NCGC00094918-07
1.2 -benzoisothiazole-3-on 1.1-dioxide
1,1-dioxo-1,2-dihydro-1lambda6-benzo[d]isothiazol-3-one
2,3-dihydro-3-oxo-1,2-benzisothiazol-1,1-dioxide
1,2-benzisothiazoline-3-one-1,1-dioxide
1.2-benzoisothiazole-3-on-1.1-dioxide
1,2-benzisothiazol-3(2h)-one-1,1-dioxide
3-keto-2h,3h-1,2-benzisothiazole 1,1-dioxide
syncal
1,1-diox-1,2-benzisothiazol-3-one
2-sulfobenzoic imide
1,1-dioxide-1,2-benzisothiazol-3(2h)-one
1,1-dioxido-3-oxo-2,3-dihydrobenzo[d]isothiazole
o-benzoic acid sulfimide
benzo-sulphinide
1,2-benzisothiazoline-3-one 1,1-dioxide
2,3-dihydro-1,2-benzoisothiazol-3-one-1,1-dioxide
benzisosulfonazole, 2,3-dihydro-3-oxo-
2,3-dihydro-1,2-benzisothiazol-3-one-1,1-dioxide
W-200289
benzo[d]isothiazol-3(2h)-one 1,1-dioxide
AB00052233_05
SR-01000389315-2
mfcd00005866
mettler-toledo calibration substance me 51143091, saccharin, traceable to primary standards (lgc)
saccharin, united states pharmacopeia (usp) reference standard
saccharin, puriss., 98%
saccharin, european pharmacopoeia (ep) reference standard
saccharin, pharmaceutical secondary standard; certified reference material
SBI-0051671.P002
Z256708526
saccharin (jp15/nf)
2,3-dihydro-3-oxo-benzisosulfonazole
o-sulfobenzoic imide
1, 2-dihydro-2-ketobenzisosulfonazole
1, 2-benzisothiazolin-3-one 1,1-dioxide
2, 3-dihydro-3-oxobenzisosulfonazole
glycophenol
3-benzisothiazolinone 1, 1-dioxide
2-sulfobenzoicimide
1,2-benzisothiazol-3(2h)-one 1,1-dioxide, 9ci
1, 2-benzisothiazol-3(2h)-one, 1,1-dioxide
neosaccharin
benzo-2-sulfiide
o-benzoylsulfimide
DB12418
F0001-2092
ulfonylurea tp3
m07 (saccharin)
saccharin (in-00581)
oxasulfuron metabolite
1,2-benzisothiazol-3(2h)-one,1,1-dioxide
1286479-01-3
o-benzoic sulfimide;o-sulfobenzimide
BCP29068
mettler-toledo calibration substance me 51143091, saccharin
CS-0013120
Q191381
BRD-K46493214-001-03-4
2,3-dihydro-1??,2-benzothiazole-1,1,3-trione
STR03759
D70140
o-sulphobenzoic imide
NCGC00094918-09
HY-Y0272
saccharin (229 degrees c) melting point standard
2,3-dihydro-1lambda6,2-benzothiazole-1,1,3-trione
EN300-18624
saccharin (usp-rs)
saccharin (ii)
1,2-benzo(d)isothiazol-3(2h)-one 1,1-dioxide
saccharin (iarc)
saccharin (ep monograph)
1,1-dioxo-1,2-dihydro-benzo(d)isothiazol-3-one
saccharin (mart.)
1,2-benzisothiazolinone, 1,1-dioxide

Research Excerpts

Overview

Saccharin droplets are a validated surrogated marker for any elements of viral size, such as coronaviruses. Saccharin-ethanol is an effective US in Pavlovian-autoshaping procedures.

ExcerptReferenceRelevance
"Saccharin is a well-known scaffold in drug discovery. "( Saccharin Aza Bioisosteres-Synthesis and Preclinical Property Comparisons.
Aurell, CJ; Chen, Y; Hayes, MA; Jonson, AC; Leek, H; Lepistö, M; Lewis, RJ; Pettersen, A; Thunberg, L, 2017
)
3.34
"Saccharin is a commonly used artificial sweetener that exhibits both sweetening and sweet inhibition activities. "( Multiple interaction modes between saccharin and sweet taste receptors determine a species-dependent response to saccharin.
Cui, M; Liu, B; Liu, M; Zhao, X, 2022
)
2.44
"Saccharin droplets are a validated surrogated marker for any elements of viral size, such as coronaviruses."( The use of a surgical helmet system with a high-efficiency particulate air filter as possible protection equipment during the coronavirus disease 2019 pandemic: a double-blinded randomized control study.
Castioni, D; Familiari, F; Galasso, O; Gasparini, G; Mercurio, M; Spina, G, 2022
)
1.44
"Saccharin is a cyclic secondary sulfonamide, which is a selective inhibitor of the tumor-associated carbonic anhydrase (CA; EC 4.2.1.1) enzymes CA IX and CA XII compared to many primary sulfonamides. "( Design, synthesis, SAR, and biological evaluation of saccharin-based hybrids as carbonic anhydrase inhibitors.
Angeli, A; Arifuddin, M; Chinchilli, KK; Danaboina, S; Nanduri, S; Royyala, VN; Singh, P; Supuran, CT; Thacker, PS, 2022
)
2.41
"The saccharin test is a simple, cost-effective, and valuable diagnostic tool to assess the mucociliary function of the ET. "( Assessment of eustachian tube function in tympanoplasty.
Hegde, MC; Meyappan, H; Prasad, KC; Prasad, SC, 2009
)
0.91
"Saccharin-ethanol is an effective US in Pavlovian-autoshaping procedures, inducing more CS-directed responding than in pseudoconditioning controls receiving CS-US random procedures."( Lever conditioned stimulus-directed autoshaping induced by saccharin-ethanol unconditioned stimulus solution: effects of ethanol concentration and trial spacing.
Festa, ED; Pohorecky, LA; Sparta, DR; Tomie, A, 2003
)
1.28
"Saccharin is a known promoter of cell transformation in C3H/10T1/2 cell cultures, but unlike 12-O-tetradecanoylphorbol 13-acetate (TPA) or mezerein, PLF mRNA abundance increases were inconsistently detected following simple addition of saccharin to the culture medium."( Combined effects of tumor promoters and serum on proliferin mRNA induction: a biomarker sensitive to saccharin, 2,3,7,8-TCDD, and other compounds at minimal concentrations promoting C3H/10T1/2 cell transformation.
Parfett, CL, 2003
)
1.26
"The saccharin sky-blue test serves as a valuable screening test."( Nasal mucociliary function in different diseases of the nose.
Hady, MR; Hassan, R; Shehata, O, 1983
)
0.75
"Saccharin is an artificial sweetener commonly used in the formulation of foods and beverages. "( Suppression of saccharin-induced mutagenicity by interferon-alpha in human RSa cells.
Suzuki, H; Suzuki, N, 1995
)
2.09
"The Saccharin test is a non-dangerous, inexpensive, suitable and repeatable method for assessing the mucociliary function of the respiratory epithelium. "( [The saccharin test in the pediatric broncho-pneumonologic outpatient clinic. A noninvasive screening method for the assessment of ciliary function of the respiratory tract in children].
Adler, S; Ballke, EH; Bruns, R; Klingbeil, P; Wiersbitzky, S, 1990
)
1.35
"Saccharin is a widely used artificial sweetener excreted in the urine which can induce dose-dependent tumours of the bladder in the animal."( [Mutagenicity of urine after ingestion of saccharin in man].
Fournier, E; Garnier, R; Thomas, G, 1986
)
1.26

Effects

Saccharin has been found to be a carcinogen only in rats. A saccharin solution has been thought to be rewarding to rabbits and is often used as an unconditioned stimulus (US)

ExcerptReferenceRelevance
"The saccharin ring system has gained considerable attention in the past decades, especially in the field of medicinal chemistry. "( Advances in the chemistry of saccharins: from synthetic novelties towards biologically active compounds.
Dolenc, MS; Jakopin, Z, 2010
)
1.21
"A saccharin solution has been thought to be rewarding to rabbits and is often used as an unconditioned stimulus (US)."( Age-dependent taste preferences in rabbits for a .025% sodium saccharin solution: preliminary findings.
Berry, SD; Dreshfield, LJ,
)
0.93
"Saccharin has been considered a compatible substance to use in chlorhexidine rinse or gel preparations; however, the effect of a range of concentrations has not been studied."( Effect of saccharin on antibacterial activity of chlorhexidine gel.
Cury, JA; Del Bel Cury, AA; Francisco, SB; Koo, H; Rocha, EP, 2000
)
1.43
"Saccharin has been found to be a carcinogen only in rats and only if administered over two generations."( Saccharin: past, present, and future.
Cohen, SM, 1986
)
2.44
"Saccharin has been reported to induce urinary bladder tumors in multigeneration rat feeding studies and to promote bladder carcinogenesis in rats initiated with known bladder carcinogens. "( The effects of saccharin on the development of neoplastic lesions initiated with N-methyl-N-nitrosourea in the rat urothelium.
Delongchamp, RR; Gaylor, DW; Haskin, MG; Kadlubar, FF; Sheldon, WG; West, RW, 1986
)
2.07
"Saccharin has successfully survived a half century of scrutiny of its safety. "( Highlights in the history of saccharin toxicology.
Oser, BL,
)
1.87

Actions

ExcerptReferenceRelevance
"Saccharin may produce an aversive taste because it stimulates receptor sites sensitive to substances bitter to man as well as those sensitive to sugars."( Taste rejection of nonnutritive sweeteners in cats.
Bartoshuk, LM; Hoff, LA; Jacobs, HL; Nichols, TL; Ryckman, JJ, 1975
)
0.98

Treatment

Saccharin treatment significantly altered amino acids, lipids, energy metabolism and specifically, bile acids in the plasma metabolome. When saccharin was cotreated with 0.25-1.0 ppm spinosad, an additive insecticidal activity was observed only at high concentrations. Saccharin gave marked caecal enlargement but had no effect on bacterial concentration at either treatment period.

ExcerptReferenceRelevance
"Saccharin treatment significantly altered amino acids, lipids, energy metabolism and specifically, bile acids in the plasma metabolome."( Investigating the gut microbiome and metabolome following treatment with artificial sweeteners acesulfame potassium and saccharin in young adult Wistar rats.
Cameron, HJ; Driemert, P; Giri, V; Haake, V; Kamp, H; Murali, A; Rietjens, IM; Sperber, S; van Ravenzwaay, B; Walk, T; Zickgraf, FM, 2022
)
1.65
"Saccharin treatment prevented reduction in hippocampal enkephalin."( Saccharin and naltrexone prevent increased pain sensitivity and impaired long-term memory induced by repetitive neonatal noxious stimulation: role of BDNF and enkephalin.
Alazzani, M; Alhusban, AY; Alzoubi, KH; Bawaane, A; Khabour, OF; Nuseir, KQ, 2021
)
2.79
"When saccharin was cotreated with 0.25-1.0 ppm spinosad, an additive insecticidal activity was observed only at high concentrations of saccharin."( Alteration of unfolded protein responses and autophagy signaling represented the molecular basis underlying saccharin toxicity to Drosophila (Diptera: Drosophilidae).
Kim, AY; Koh, YH; Mai, LX; Osabutey, AF; Seo, BY, 2021
)
1.29
"Saccharin treatment of 3T3-L1 cells and primary mesenchymal stem cells rapidly stimulated phosphorylation of Akt and downstream targets with functions in adipogenesis such as cAMP-response element-binding protein and FOXO1; however, increased expression of peroxisome proliferator-activated receptor γ and CCAAT/enhancer-binding protein α was not observed until relatively late in differentiation."( Artificial sweeteners stimulate adipogenesis and suppress lipolysis independently of sweet taste receptors.
Assadi-Porter, FM; Cawthorn, WP; Evans, CR; Gallagher, K; Learman, BS; MacDougald, OA; Mori, H; Ning, X; Parlee, SD; Scheller, EL; Simon, BR; Tyrberg, B, 2013
)
1.11
"Saccharin treatment also resulted in a dose-dependent increase in the stool content of carbohydrate soluble in 1 N-NaOH."( Effect of saccharin ingestion on stool composition in relation to caecal enlargement and increased stool hydration.
Anderson, RL, 1983
)
1.39
"Saccharin treatment gave marked caecal enlargement but had no effect on bacterial concentration at either treatment period, and significantly decreased beta-glucuronidase, nitrate reductase and sulphatase activities/g caecal contents."( Modification of rat caecal microbial biotransformation activities by dietary saccharin.
Bearne, CA; Mallett, AK; Rowland, IR, 1985
)
1.22
"Saccharin-treated animals in both generations showed increased urinary excretion of indican."( The microbial metabolism of tryptophan in rats fed a diet containing 7.5% saccharin in a two-generation protocol.
Renwick, AG; Sims, J,
)
1.08

Toxicity

Rats made ill after drinking saccharin and subsequently administered a "safe" exposure to saline (or casein hydrolysate) showed an enhanced preference for the safe fluid. These results suggest that aspartame and Saccharin could be toxic to the human circulation system as well as embryonic development.

ExcerptReferenceRelevance
" Rats made ill after drinking saccharin and subsequently administered a "safe" exposure to saline (or casein hydrolysate) evidenced an enhanced preference for the safe fluid (relative to either a third, slightly aversive, solution or to water) when compared to controls in which saccharin was not previously poisoned."( Conditioned and latent inhibition in taste-aversion learning: clarifying the role of learned safety.
Best, MR, 1975
)
0.54
" A useful model for studying memory formation is gustatory memory, a type of memory in which a novel taste may become either safe by not being followed by negative consequences (attenuation of neophobia, AN), or aversive by being followed by post-digestive malaise (conditioned taste aversion, CTA)."( Safe taste memory consolidation is disrupted by a protein synthesis inhibitor in the nucleus accumbens shell.
Bermúdez-Rattoni, F; Guzmán-Ramos, K; Pedroza-Llinás, R; Ramírez-Lugo, L; Zavala-Vega, S, 2009
)
0.35
" These results suggest that aspartame and saccharin could be toxic to the human circulation system as well as embryonic development via impairment of lipoprotein function."( Modified high-density lipoproteins by artificial sweetener, aspartame, and saccharin, showed loss of anti-atherosclerotic activity and toxicity in zebrafish.
Cho, KH; Choi, I; Kim, J; Kim, JY; Park, KH, 2015
)
0.91
" We found that acute inhibition of Arc protein synthesis through the infusion of antisense oligonucleotides administered in the IC before a novel taste presentation, affected consolidation of a safe taste memory trace (ST) but spared consolidation of conditioned taste aversion (CTA)."( Differential requirement of de novo Arc protein synthesis in the insular cortex and the amygdala for safe and aversive taste long-term memory formation.
Bermúdez-Rattoni, F; Guzmán-Ramos, K; Morin, JP; Osorio-Gómez, D; Venkataraman, A, 2018
)
0.48
" In the present study, the potential developmental toxicity of drugs was divided into three classes (1: non-developmentally toxic, 2: weakly developmentally toxic and 3: strongly developmentally toxic) according to the EST criteria."( A novel screening test to predict the developmental toxicity of drugs using human induced pluripotent stem cells.
Aikawa, N, 2020
)
0.56
" Thus, their potential toxic effects have received extensive attention."( Phenotyping Aquatic Neurotoxicity Induced by the Artificial Sweetener Saccharin at Sublethal Concentration Levels.
Dong, G; Du, L; Gao, J; Han, G; Li, M; Li, X; Zhang, L, 2021
)
0.86
"The purpose of this study was to develop a new control method for Drosophila using saccharin sodium dihydrate (saccharin), an artificial sweetener that is safe for humans and the environment, and to elucidate its mode of action."( Alteration of unfolded protein responses and autophagy signaling represented the molecular basis underlying saccharin toxicity to Drosophila (Diptera: Drosophilidae).
Kim, AY; Koh, YH; Mai, LX; Osabutey, AF; Seo, BY, 2021
)
1.06

Pharmacokinetics

ExcerptReferenceRelevance
" After intravenous administration of the non-nutritive sweetener, saccharin (10 mg/kg), to normal volunteers; the plasma concentration--time curve fitted a two-compartment open model with a terminal half-life of 70 min."( The pharmacokinetics of saccharin in man.
Burgess, CD; Renwick, AG; Sweatman, TW, 1981
)
0.81

Compound-Compound Interactions

New sensitive and robust assay using Fourier Transform Near-Infrared Spectroscopy (FT-NIRS) combined with partial least square (PLS) multivariate methods has been developed for detection and quantification of saccharin adulteration.

ExcerptReferenceRelevance
"30 mg/kg) alone, and in combination with the BDZ receptor antagonists flumazenil, ZK 93426, and CGS 8216 (20 mg/kg) in selectively bred alcohol-preferring (P) rats provided a two-bottle choice test between ethanol (EtOH) (10% v/v), and a palatable saccharin (0."( Effects of the benzodiazepine inverse agonist RO19-4603 alone and in combination with the benzodiazepine receptor antagonists flumazenil, ZK 93426 and CGS 8216, on ethanol intake in alcohol-preferring (P) rats.
Cason, CR; Cox, R; Duemler, SE; Greene, TL; Hite, ML; June, HL; Li, TK; Lumeng, L; Mellon-Burke, J; Murphy, JM; Torres, L; Williams, JA, 1996
)
0.48
" In present study, a new sensitive and robust assay using Fourier Transform Near-Infrared Spectroscopy (FT-NIRS) combined with partial least square (PLS) multivariate methods has been developed for detection and quantification of saccharin adulteration in different commercial fruit juice samples."( Applications of FT-NIRS combined with PLS multivariate methods for the detection & quantification of saccharin adulteration in commercial fruit juices.
Abbas, G; Al-Harrasi, A; Alameri, S; Albroumi, M; Alghawi, S; Allaham, B; Farooq, S; Gilani, SA; Haq, QMI; Hussain, J; Jabeen, F; Mabood, F, 2018
)
0.88
" In our study, the effects of several polysaccharides such as alginate, κ-carrageenan, locust bean gum, gellan gum, xanthan gum and their combination with various prebiotic components (resistant starch, lactulose, lactosucrose) on encapsulation of probiotic Lactobacillus casei 01 strain were studied."( Effects of various polysaccharides (alginate, carrageenan, gums, chitosan) and their combination with prebiotic saccharides (resistant starch, lactosucrose, lactulose) on the encapsulation of probiotic bacteria Lactobacillus casei 01 strain.
Antal, O; Bujna, E; Gupta, VK; Juhász, R; Kun, S; Ladányi, M; Nguyen, QD; Sudheer, S; Szécsi, A; Ta, LP, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" In the bioavailability studies, a significantly longer half-life (approximately 5-7 times) for 17B-estradiol was observed when the prodrug was given orally than when 17 beta-estradiol was given orally or when the prodrug or 17 beta-estradiol were given intravenously."( A prodrug approach to increasing the oral potency of a phenolic drug. Part 2. Pharmacodynamics and preliminary bioavailability of an orally administered O-(imidomethyl) derivative of 17 beta-estradiol.
Curry, SH; Katovich, MJ; Patel, J; Prankerd, RJ; Sloan, KB, 1995
)
0.29
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" However, the in-vivo bioavailability of cocrystals has rarely been addressed."( Bioavailability of indomethacin-saccharin cocrystals.
Alhalaweh, A; Cho, W; Hwang, SJ; Jung, MS; Kim, JS; Kim, MS; Velaga, SP, 2010
)
0.64
" Finally, a bioavailability study for the formulations was conducted in beagle dogs."( Bioavailability of indomethacin-saccharin cocrystals.
Alhalaweh, A; Cho, W; Hwang, SJ; Jung, MS; Kim, JS; Kim, MS; Velaga, SP, 2010
)
0.64
" The in-vivo bioavailability of the IND-SAC cocrystals in dogs was significantly higher (ANOVA, P<0."( Bioavailability of indomethacin-saccharin cocrystals.
Alhalaweh, A; Cho, W; Hwang, SJ; Jung, MS; Kim, JS; Kim, MS; Velaga, SP, 2010
)
0.64
"The study indicates that the improved aqueous solubility of the cocrystals leads to improved bioavailability of IND."( Bioavailability of indomethacin-saccharin cocrystals.
Alhalaweh, A; Cho, W; Hwang, SJ; Jung, MS; Kim, JS; Kim, MS; Velaga, SP, 2010
)
0.64
" This coamorphous system provides a feasible way to process drugs with low solubility into substances with enhanced dissolution and stabilized amorphous state that could be conducive to greater bioavailability than the crystalline drug."( Coamorphous repaglinide-saccharin with enhanced dissolution.
Gao, Y; Liao, J; Qi, X; Zhang, J, 2013
)
0.7
" The solubility and dissolution properties of co-crystals can allow to increase the bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs)."( Indomethacin co-crystals and their parent mixtures: does the intestinal barrier recognize them differently?
Beggiato, S; Bertolasi, V; Dalpiaz, A; Ferraro, L; Ferretti, V; Pavan, B; Spisni, E; Spizzo, F, 2015
)
0.42
" Therefore, CEL-ADI and CEL-SAC eutectics may offer a novel formulation strategy to enhance the solubility and oral bioavailability of CEL."( Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate.
Abuzar, SM; Hong, SH; Hwang, SJ; Hyun, SM; Joo, Y; Kang, H; Kwon, KA; Lee, BJ; Lee, S; Velaga, S, 2019
)
0.73
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Ligustrazine (or Tetramethylpyrazine, TMP) is an active pharmaceutical ingredient that faces the challenges of bitter taste and low oral bioavailability by the commercial phosphate salt (TMP-Pho)."( Simultaneous taste-masking and oral bioavailability enhancement of Ligustrazine by forming sweet salts.
He, X; Hu, S; Li, Q; Sun, CC; Wang, C; Zhao, X, 2020
)
0.56
"Amorphous and co-amorphous formulations have been used to enhance the solubility and bioavailability of poorly water-soluble drugs."( Measurement of the amorphous fraction of olanzapine incorporated in a co-amorphous formulation.
da Costa, NF; Fernandes, AI; Pinto, JF, 2020
)
0.56
"This study aimed to improve the in vitro dissolution, permeability and oral bioavailability of adefovir dipivoxil (ADD) by cocrystal technology and clarify the important role of coformer selection on the cocrystal's properties."( Effect of Coformer Selection on In Vitro and In Vivo Performance of Adefovir Dipivoxil Cocrystals.
Gao, Y; Li, L; Ma, K; Pang, Z; Qian, S; Wei, Y; Zhang, J; Zheng, D, 2021
)
0.62
"Coformer selection had an important role on cocrystal's properties, and cocrystallization of ADD with a suitable coformer was an effective approach to enhance both dissolution and bioavailability of ADD."( Effect of Coformer Selection on In Vitro and In Vivo Performance of Adefovir Dipivoxil Cocrystals.
Gao, Y; Li, L; Ma, K; Pang, Z; Qian, S; Wei, Y; Zhang, J; Zheng, D, 2021
)
0.62
"The preparation of amorphous and co-amorphous systems (CAMs) effectively addresses the solubility and bioavailability issues of poorly water-soluble chemical entities."( Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization.
da Costa, NF; Daniels, R; Fernandes, AI; Pinto, JF, 2022
)
0.72

Dosage Studied

Sodium saccharin dosing did not result in an increased incidence of tumors in either the bladder or liver and is therefore not considered to be a promoter of carcinogenesis at these sites in the mouse.

ExcerptRelevanceReference
" The risk ratio for ever versus never used is 1-6 for males (P=0-009, one-tailed test), and a significant dose-response relationship was obtained for both duration and frequency of use."( Artificial sweeteners and human bladder cancer.
Burch, JD; Chambers, LW; Fodor, G; Gordon, P; Howe, GR; Miller, AB; Morrison, B; Weldon, L; Winsor, GM, 1977
)
0.26
" These elements were divided into 4 general categories: design, including selection of test animals, basal diet, dosage form and doses of test substance, route of administration, and duration of exposure; observations, including gross observations during life and at necropsy, clinical tests, and histopathology; performance, including conduct of the test and animal husbandry; and analytical procedures, including chemical and statistical analyses."( Comparison of studies on saccharin and sodium nitrite.
Morgenroth, VH; Taylor, JM, 1979
)
0.56
"Rats 24-hr water deprived were injected IP with a fixed amount (10 ml/kg) of solution of various concentrations of LiCl and NaCl in dosage ranges which in previous experiments either increased or had no effect on water intake."( NaCl and LiCl efficacy in the induction of aversion for quinine and saccharin solutions immediately following injection.
Kutscher, CL; Lisch, M; Wright, WA, 1977
)
0.49
" However, no dose-response relationship was demonstrated between LUT cancer and usual daily coffee consumption or "cup-years" of coffee drinking."( Coffee drinking and cancer of the lower urinary tract.
Cole, P; Simon, D; Yen, S, 1975
)
0.25
" Since conversion to cyclohexylamine (CHA) was found to occur in many of the rats, particularly in the higher dosage groups, it was included as an added insult in the diets of about half the animals during the last quarter of the 2-year test period."( Chronic toxicity study of cyclamate: saccharin (10: 1) in rats.
Carson, S; Cox, GE; Oser, BL; Sternberg, SS; Vogin, EE, 1975
)
0.53
" The degree of aversion was related to the maintenance dosage of morphine."( Conditioned flavor aversions for assessing precipitated morphine abstinence in rats.
Pilcher, CW; Stolerman, IP, 1976
)
0.26
" The carcinogenic dose-response relationship for genotoxic chemicals (such as 2-acetylaminofluorene) was also due in part to increased cell proliferation."( Cell proliferation in carcinogenesis.
Cohen, SM; Ellwein, LB, 1990
)
0.28
" Studies of the dose-response relationships have also shown no consistent pattern."( Saccharin/cyclamates: epidemiological evidence.
Armstrong, BK, 1985
)
1.71
" However, sodium saccharin dosing did not result in an increased incidence of tumors in either the bladder or liver and is therefore not considered to be a promoter of carcinogenesis at these sites in the mouse."( The effect of lifetime sodium saccharin dosing on mice initiated with the carcinogen 2-acetylaminofluorene.
Dooley, KL; Frederick, CB; Kadlubar, FF; Kodell, RL; Sheldon, WG, 1989
)
0.91
" The dose-response curves were obtained with good precision and allowed a discrimination between the teratogenetic and unspecific toxic effects and a comparison of the toxic potency of the six drugs."( Routine teratogenicity test that uses chick embryos in vitro.
Burnand, MB; Kucera, P, 1987
)
0.27
" Experiment 1 established a dose-response function for inhibition of intake by naloxone (NAL) in short (60 min) 2-bottle tests."( Opiate blockade inhibits saccharin intake and blocks normal preference acquisition.
Lynch, WC, 1986
)
0.57
"5%) for 6 weeks excreted increased amounts of p-cresol, but many excreted negligible amounts so that the overall dose-response relationship was bell shaped."( The effect of saccharin ingestion on the excretion of microbial amino acid metabolites in rat and man.
Lawrie, CA; Renwick, AG, 1987
)
0.63
"Carcinogenic risk assessment based on low-dose extrapolation of dose-response relationships is characterized by a significant level of uncertainty."( Reproducibility of low-dose extrapolation procedure: comparison of estimates obtained using different rodent species and strains.
Bucchi, AR; Lupi, C; Zapponi, GA, 1988
)
0.27
"This study analyzes a set of dose-response curves relative to promoter carcinogens administered to experimental animals with or without initiator pretreatment."( Dose-response relationships in rodents of promoter carcinogens: a tentative interpretation of some downward trends.
Bucchi, AR; Gabriele, M; Lupi, C; Zapponi, GA, 1988
)
0.27
"This paper introduces a dose-response model for toxic quantal response data based on hit theory applied to the dose unit as transformed by a nonlinear kinetic equation."( A dose-response model incorporating nonlinear kinetics.
Rai, K; Van Ryzin, J, 1987
)
0.27
" Dosed animals were kept in metabolism cages for 48 h to monitor urinary and fecal excretion of the label."( Urinary excretion of orally administered oxalic acid in saccharin and o-phenylphenol-fed NMRI mice.
Salminen, E; Salminen, S, 1986
)
0.52
" The steep slope of the dose-response curve indicated a rapid decline in tumour incidence with decreasing dose."( Evaluation of the dose response and in utero exposure to saccharin in the rat.
Carlborg, FW; Frith, CH; Geil, RG; Goldenthal, EI; Richter, WR; Schoenig, GP,
)
0.38
"The results from a recently completed large experiment with rats exposed to saccharin show that the dose-response function is much steeper than was previously assumed."( A cancer risk assessment for saccharin.
Carlborg, FW,
)
0.65
" Although this dose-response relationship was evident for both males and females, the minimal effective dose for inducing an aversion was lower for males, an effect consistent with previous work examining sex differences in taste aversion learning."( Sex differences in taste aversion learning: an analysis of the minimal effective dose.
Dacanay, RJ; Mastropaolo, JP; Olin, DA; Riley, AL,
)
0.13
" Generally, carcinogenicity is a result of the intrinsic property of a chemical and is independent of dosage and duration of exposure; however, the detection of carcinogenicity is dose-related."( Experimental identification of genitourinary carcinogens.
Sontag, JM, 1980
)
0.26
" Of the saccharin derivatives, 3-oxo-1,2-benzisothiazoline-2-propionic acid 1,1-dioxide was the most effective in lowering serum cholesterol levels by 53% after 16 days dosing and 3-oxo-1,2-benzisothiazoline-2-valeric acid 1,1-dioxide lowered serum triglycerides 56% after 14 days dosing."( Hypolipidemic activity of phthalimide derivatives. 3. A comparison of phthalimide and 1,2-benzisothiazolin-3-one 1,1-dioxide derivatives to phthalimidine and 1,2-benzisothiazoline 1,1-dioxide congeners.
Chapman, JM; Cocolas, GH; Hall, IH, 1983
)
0.7
" 1) Physical modifiers: Route of administration, medium (vehicle) of carcinogens, detergents, dosage (concentration), period (frequency) of administration, exposure time, and condition of mucus."( [Experimental carcinogenesis of the stomach and its modifiers].
Takahashi, M, 1983
)
0.27
" None of the incidences or numbers of these lesions were significantly different in any of the other saccharin-treated groups when compared to the group treated with BBN alone except for the incidences of two types of hyperplasias in the female rats dosed with 10,000 ppm saccharin."( Dose response of saccharin in induction of urinary bladder hyperplasias in Fischer 344 rats pretreated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Hagiwara, A; Imaida, K; Ito, N; Nakanishi, K; Shibata, M; Tatematsu, M, 1980
)
0.82
" The slope of the X-ray dose-response curve of Allium roots derived from the meristematic regions was lower than that derived from cells in the F1 region."( The improved Allium/Vicia root tip micronucleus assay for clastogenicity of environmental pollutants.
Arreola, GA; Ma, TH; McConnell, H; Rabago, EV; Xu, C; Xu, Z; Zhang, H, 1995
)
0.29
" There was a significant dose-response relationship with lifelong coffee drinking and alcohol consumption; however the risk estimates were only significantly elevated for the heaviest drinkers."( Relative importance of risk factors in bladder carcinogenesis: some new results about Mediterranean habits.
Bontoux, J; Daurès, JP; Festy, B; Grémy, F; Momas, I, 1994
)
0.29
"A co-carcinogenicity experiment was conducted with female Sprague-Dawley rats in which the effects of short-term sodium saccharin dosing and initiation with a direct-acting carcinogen were examined in the urinary bladder."( Study of sodium saccharin co-carcinogenicity in the rat.
Allen, RR; Gaylor, DW; Kadlubar, FF; Sheldon, WG; West, RW, 1994
)
0.84
" We present simple methods for combining dose information from the study of interest with dose-response data from other epidemiologic studies or animal studies to derive plausible hypothesized effect levels."( Resolving discrepancies among studies: the influence of dose on effect size.
Hertz-Picciotto, I; Neutra, RR, 1994
)
0.29
" Cell proliferation can affect the dose-response curve for genotoxic carcinogens and is the basis for carcinogenicity by nongenotoxic agents."( Role of cell proliferation in regenerative and neoplastic disease.
Cohen, SM, 1995
)
0.29
" NaSac-induced cell damage and proliferation have been proposed as important factors in tumor promotion, and dose-response information demonstrating a threshold for these parameters is available."( Saccharin mechanistic data and risk assessment: urine composition, enhanced cell proliferation, and tumor promotion.
Whysner, J; Williams, GM, 1996
)
1.74
" The results showed retention-interval effects only at medium and high dosage levels, but not following a weak-intensity US."( Unconditioned stimulus intensity and retention interval effects.
Batsell, WR; George, JW, 1996
)
0.29
" In this study, after overnight fasting the influence of a 25 g oral dosage of glucose on a range of measures of memory performance was investigated in healthy young female participants."( Glucose and memory: fractionation of enhancement effects?
Foster, JK; Lidder, PG; Sünram, SI, 1998
)
0.3
" The public health implication of this lack of linearity in the low-dose area of the dose-response curve raises the question of whether low doses of carcinogens will reduce cancer risk."( Can the concept of hormesis Be generalized to carcinogenesis?
Baldwin, LA; Calabrese, EJ, 1998
)
0.3
", 10 and 20 mg/kg, respectively), and there was no evidence for a drug-induced left- or rightward shift of the ethanol unit dose-response curve, the effects of ipsapirone are considered to be nonselective."( Effects of the 5-HT1A receptor agonist ipsapirone on operant self-administration of ethanol in the rat.
De Vry, J; Haussels, A; Manze, B; Schreiber, R, 1999
)
0.3
" The present study used food-induced drinking with oral testosterone self-administration in hamsters to determine (1) the dose-response for testosterone reward, (2) links between testosterone self-administration and voluntary exercise, and (3) factors predicting individual differences in androgen intake."( Oral testosterone self-administration in male hamsters: dose-response, voluntary exercise, and individual differences.
Wood, RI, 2002
)
0.31
" In Experiment 2, a similar dose-response function was obtained with either the empty tube or a lever as the operant."( Cocaine-induced suppression of saccharin intake: a model of drug-induced devaluation of natural rewards.
Grigson, PS; Twining, RC, 2002
)
0.6
" Analysis of the spike discharges also shows a positive dose-response for the "deterrent" cell following stimulation with Na-saccharin and denatonium benzoate."( Saccharin stimulates the "deterrent" cell in the blowfly: behavioral and electrophysiological evidence.
Crnjar, R; Liscia, A; Masala, C; Solari, P; Sollai, G, 2004
)
1.97
" However, different dosing schedules were needed for the two drugs to induce this effect."( Attenuation of high sweet solution preference by mood stabilizers: a possible mouse model for the increased reward-seeking domain of mania.
Einat, H; Flaisher-Grinberg, S; Overgaard, S, 2009
)
0.35
" After acquisition, rats were tested with a cumulative dose-response procedure (0-18 mg/kg) for 12 consecutive days."( The effects of home-cage access to a sweet solution on the discriminative stimulus effects of cocaine.
Kohut, SJ; Riley, AL, 2010
)
0.36
" The present set of experiments examined the dose-response and sex-related differences induced by repeated binge ethanol administration during adolescence on sweetened ethanol (Experiment 1) or saccharin (Experiment 2) intake in young adulthood."( Repeated binge ethanol administration during adolescence enhances voluntary sweetened ethanol intake in young adulthood in male and female rats.
Alipour, KK; Kirstein, CL; Maldonado-Devincci, AM; Michael, LA, 2010
)
0.55
"25 microg) of ICS significantly increased responding on the ethanol lever; after the 7-day dosing regimen, responding on the ethanol lever returned to control levels."( Serotonin-3 receptors in the posterior ventral tegmental area regulate ethanol self-administration of alcohol-preferring (P) rats.
Bell, RL; McBride, WJ; Murphy, JM; Oster, SM; Pommer, TJ; Rodd, ZA; Toalston, JE, 2010
)
0.36
" After having equated drug dosage in terms of conditioned taste avoidance, 13-day-old rats were given a single pairing of a novel taste (saccharin) and either LiCl or ethanol (2."( A comparison between taste avoidance and conditioned disgust reactions induced by ethanol and lithium chloride in preweanling rats.
Arias, C; Molina, JC; Pautassi, RM; Spear, NE, 2010
)
0.56
" Results from the post-LgA dose-response ShA condition indicated that both LoS and HiS vehicle-treated and progesterone-treated rats earned more infusions than pre-LgA, but mainly at low doses."( Effects of progesterone on escalation of intravenous cocaine self-administration in rats selectively bred for high or low saccharin intake.
Anker, JJ; Carroll, ME; Holtz, NA, 2012
)
0.59
"Repeated dosing (0."( Varenicline and cytisine: two nicotinic acetylcholine receptor ligands reduce ethanol intake in University of Chile bibulous rats.
Busto, UE; Cassels, BK; Gysling, K; Quintanilla, ME; Sotomayor-Zárate, R; Tampier, L, 2013
)
0.39
"Voluntary drinking of 20 % ethanol in an every-other-day (EOD) availability pattern and the dose-response relationship of ethanol conditioned taste aversion (CTA) were assessed in male and female adolescent and adult rats."( Effect of sex on ethanol consumption and conditioned taste aversion in adolescent and adult rats.
Francis, R; Keistler, C; Kuhn, CM; MacDonald, A; O'Neill, L; Schramm-Sapyta, NL, 2014
)
0.4
" In this study, we examined whether mice pretreated with chronic nicotine, at a dosing regimen that results in maximal nicotinic acetylcholine receptor (nAChR) upregulation, would display evidence of nicotine-dependent behaviour during nicotine self-administration."( Chronic nicotine pretreatment is sufficient to upregulate α4* nicotinic receptors and increase oral nicotine self-administration in mice.
Nashmi, R; Renda, A, 2014
)
0.4
" Dose-response curves (0."( Drinking sucrose or saccharin enhances sensitivity of rats to quinpirole-induced yawning.
Bentley, TA; France, CP; Kilborn, DJ; Koek, W; Serafine, KM, 2015
)
0.74
"Ethionamide (ETH), a Biopharmaceutics Classification System class II drug, is a second-line drug manufactured as an oral dosage form by Pfizer to treat tuberculosis."( Mechanochemistry applied to reformulation and scale-up production of Ethionamide: Salt selection and solubility enhancement.
da Silva, CC; de Melo, CC; Ellena, J; Pereira, CC; Rosa, PC, 2016
)
0.43
" Herein, we demonstrate that dose-response relationships existed with regard to administration of saccharin or sucrose to mice for 35 days, and this association involved testis-expressed sweet-tasting molecules (taste receptor type 1 subunit 3 [T1R3]; G protein alpha-gustducin [Galpha])."( Effects of Daily Exposure to Saccharin and Sucrose on Testicular Biologic Functions in Mice.
Gong, T; Mao, DG; Nagaoka, K; Shi, FX; Taya, K; Watanabe, G; Wei, QW, 2016
)
0.94
" A double-blind, randomized crossover dose-response study was conducted to assess the usefulness of urinary LCS excretions (from both fasting spot and a full 24-h urine collection) for investigating recent intakes."( Application of Liquid Chromatography-Tandem Mass Spectrometry To Determine Urinary Concentrations of Five Commonly Used Low-Calorie Sweeteners: A Novel Biomarker Approach for Assessing Recent Intakes?
Dowey, LRC; Gallagher, AM; Logue, C; McClean, S; Strain, JJ; Verhagen, H, 2017
)
0.46
"Pharmaceutical manufacturing processes are necessary to make solid dosage form even in cocrystal formation."( Kinetics Study of Cocrystal Formation Between Indomethacin and Saccharin Using High-Shear Granulation With In Situ Raman Spectroscopy.
Ashizawa, K; Hattori, Y; Otsuka, M; Tanaka, R, 2019
)
0.75
"Formulation of a cocrystal into a solid pharmaceutical dosage form entails numerous processing steps during which there is risk of dissociation."( Formation of Indomethacin-Saccharin Cocrystals during Wet Granulation: Role of Polymeric Excipients.
Duggirala, NK; Hattori, Y; Otsuka, M; Suryanarayanan, R; Tanaka, R, 2020
)
0.86
" The development of tools capable of quantifying and monitoring the recrystallization of amorphous materials is required to ensure the delivery of solid dosage forms with improved performance."( Measurement of the amorphous fraction of olanzapine incorporated in a co-amorphous formulation.
da Costa, NF; Fernandes, AI; Pinto, JF, 2020
)
0.56
" Besides resistance under the processing conditions of the dosage forms considered, OLZ-CAMs presented a higher solubility and dissolution rate than the respective crystalline counterpart."( Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization.
da Costa, NF; Daniels, R; Fernandes, AI; Pinto, JF, 2022
)
0.72
" Further studies in which the potential personalized microbial response to NNSs consumption is acknowledged, and that include longer intervention protocols, larger cohorts, and more realistic sweetener dosage are needed to broaden these findings."( Effect of low-and non-calorie sweeteners on the gut microbiota: A review of clinical trials and cross-sectional studies.
Gauthier, E; Milagro, FI; Navas-Carretero, S, 2024
)
1.44
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (45 Product(s))

Product Categories

Product CategoryProducts
Other24
Snacks, Sweet snacks, Biscuits and cakes, Cakes, Muffins, Fruit muffins, Blueberry muffins1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Fruits et produits dérivés, Produits déshydratés, Aliments à base de plantes séchées, Fruits secs, Bananes séchées1
Produits laitiers, Produits fermentés, Produits laitiers fermentés, Fromages, en:cooked-pressed-cheeses, Fromages de France, Comté, en:aoc-cheeses, en:labeled-cheeses1
Dairies, Milks1
Meals, Prepared salads, Salads1
Beverages, Alcoholic beverages, Hard seltzer1
Cibi e bevande a base vegetale, Cibi a base vegetale, Grassi, Grassi vegetali, Prodotti dell'ulivo, Olio vegetale, Olio di oliva, Olio extra vergine di oliva, Olio vergine di oliva1
Boissons, Sirops, Sirops aromatisés1
Plant-based foods and beverages, Plant-based foods, Fruits and vegetables based foods1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Fruits et produits dérivés, Produits déshydratés, Aliments à base de plantes séchées, Fruits secs, Raisins secs, Raisins secs Sultanines1
Alimentos y bebidas de origen vegetal, Alimentos de origen vegetal, Desayunos, Cereales y patatas, Cereales y derivados, Cereales para el desayuno, Muesli1
Dairies,Curd cheese1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Petit-déjeuners, Produits à tartiner, Pâtes à tartiner végétales, Produits à tartiner sucrés, Confitures et marmelades, Confitures, Confitures de fruits rouges, Confitures de myrtilles1
Fertiggerichte, Fertigsalate1
Sandwiches, en:Wraps, Tortilla1
Mléčné výrobky, Kvašené potraviny, en:Desserts, en:Fermented milk products, en:Dairy desserts, en:Fermented dairy desserts, en:Fermented dairy desserts with fruits, Jogurt, Ovocné jogurty1
Aliments et boissons à base de végétaux, Boissons, Aliments d'origine végétale, Boissons chaudes, Cafés, Dosettes, Cafés en dosettes, Dosettes Dolce Gusto, Cafés en dosettes compatible Dolce Gusto, Boissons avec sucre ajouté1
Aliments et boissons à base de végétaux, Boissons, Aliments d'origine végétale, Boissons chaudes, Cafés, Dosettes, Cafés décaféinés, Cafés en dosettes, Cafés en dosettes compatible Nespresso, Lungo decaffeinato1
Alimentos y bebidas de origen vegetal, Bebidas, Alimentos de origen vegetal, Bebidas para tomar calientes, Cafés, en:Capsules, Capsulas de cafe, Cápsulas de café compatibles con Nespresso1
Condiments, Sauces, Groceries1
Slim Fast Fat Bomb1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved

Roles (3)

RoleDescription
sweetening agentSubstance that sweeten food, beverages, medications, etc.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
1,2-benzisothiazoleA benzothiazole consisting of a benzene ring fused to an isothiazole.
N-sulfonylcarboxamideA mixed diacylamine resulting from the formal condensation of the nitrogen of a carboxamide with a sulphonic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (57)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency35.48130.177814.390939.8107AID2147
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.29850.006038.004119,952.5996AID1159521
TDP1 proteinHomo sapiens (human)Potency11.88560.000811.382244.6684AID686979
AR proteinHomo sapiens (human)Potency0.00170.000221.22318,912.5098AID743042
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency68.10160.001022.650876.6163AID1224838
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency51.15370.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency56.82950.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.91750.000229.305416,493.5996AID743069
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency33.48890.001024.504861.6448AID743212
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.19590.023723.228263.5986AID588543; AID743223
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency22.38720.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency68.10160.000723.06741,258.9301AID743085
activating transcription factor 6Homo sapiens (human)Potency0.06010.143427.612159.8106AID1159516
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00250.010039.53711,122.0200AID588545
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency3.04200.000323.4451159.6830AID743067
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency19.95260.65619.452025.1189AID927
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency35.48130.010323.856763.0957AID2662
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.58960.000627.21521,122.0200AID651741
gemininHomo sapiens (human)Potency0.00080.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency0.00560.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency30.30170.002319.595674.0614AID651631
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency19.95261.584913.004325.1189AID927
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase Astrosclera willeyanaKi0.75100.03201.51729.6000AID644379
Carbonic anhydrase Sulfurihydrogenibium sp. YO3AOP1Ki0.87600.00450.16240.8760AID1268964
Carbonic anhydrase Stylophora pistillataKi0.04030.00000.686710.0000AID436565; AID552130
Carbonic anhydraseStylophora pistillataKi0.10400.00000.50715.7100AID552131
Carbonic anhydrase 12Homo sapiens (human)Ki0.63510.00021.10439.9000AID1076530; AID1126903; AID1275627; AID1466467; AID1472890; AID1581515; AID1626174; AID321159
Carbonic anhydrase 1Homo sapiens (human)Ki18.31160.00001.372610.0000AID1076532; AID1126895; AID1142833; AID1188134; AID1194024; AID1195369; AID1262263; AID1268962; AID1275624; AID1275913; AID1287517; AID1434427; AID1466464; AID1472887; AID1581510; AID1626170; AID321156; AID349605; AID367820; AID414955; AID427125; AID436563; AID497127; AID552127; AID587130; AID612725; AID644380; AID711214; AID725955; AID729566; AID743515
Carbonic anhydrase 2Homo sapiens (human)Ki5.97550.00000.72369.9200AID1061069; AID1076533; AID1126896; AID1142834; AID1188135; AID1194025; AID1195370; AID1240217; AID1262264; AID1268963; AID1275625; AID1275912; AID1278409; AID1287518; AID1356350; AID1434428; AID1466465; AID1472888; AID1581511; AID1626171; AID321157; AID349606; AID367821; AID414956; AID427124; AID436564; AID437749; AID497129; AID552128; AID587131; AID612726; AID644381; AID648178; AID648179; AID648180; AID711213; AID725956; AID729565; AID743514
CholinesteraseHomo sapiens (human)IC50 (µMol)3.60000.00001.559910.0000AID1176929
Carbonic anhydrase 3Homo sapiens (human)Ki1,000.00000.00022.010210.0000AID301578
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki10.06000.00010.949010.0000AID1126898
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)510.00000.00030.39075.4000AID280501
Carbonic anhydrase 4Homo sapiens (human)Ki7.92000.00021.97209.9200AID1126897; AID1581512
Carbonic anhydrase 6Homo sapiens (human)Ki0.93500.00011.47109.9200AID1126900; AID552129
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Ki10.06000.00000.575110.0000AID1126898
Delta-type opioid receptorMus musculus (house mouse)Ki12.24950.00000.53939.4000AID1188134; AID1188135
Delta-type opioid receptorRattus norvegicus (Norway rat)Ki5.95900.00000.60689.2330AID1188135
Mu-type opioid receptorRattus norvegicus (Norway rat)Ki18.54000.00000.38458.6000AID1188134
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki10.06000.00001.27259.9000AID1126898
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki10.06000.00000.965010.0000AID1126898
Carbonic anhydrase 7Homo sapiens (human)Ki0.01000.00021.37379.9000AID1126901; AID1581513; AID1626172
Carbonic anhydraseSaccharomyces cerevisiae S288CKi12.50000.08200.56098.7000AID367822
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki5.95900.00000.27869.0000AID1188135
Beta-carbonic anhydrase 1Mycobacterium tuberculosis H37RvKi7.96000.00483.38419.8400AID1798985; AID349607
Carbonic anhydrase 2Mycobacterium tuberculosis H37RvKi0.79200.00902.20969.8400AID437750
Carbonic anhydrase 9Homo sapiens (human)Ki0.10240.00010.78749.9000AID1076531; AID1126902; AID1275626; AID1356351; AID1466466; AID1472889; AID1581514; AID1626173; AID321158; AID729564
Carbonic anhydrase, alpha family Hydrogenovibrio crunogenus XCL-2Ki0.93300.00250.32341.1000AID1268965
Carbonic anhydraseCandida albicans SC5314Ki11.15730.01051.44448.3470AID1799266; AID427122
Carbonic anhydrase Anopheles gambiae (African malaria mosquito)Ki0.09530.00980.51174.3600AID1195371
Delta carbonic anhydraseConticribra weissflogiiKi9.20000.04960.99789.2000AID1061066
RmtAAspergillus nidulansIC50 (µMol)510.00005.90005.90005.9000AID280502
Protein arginine N-methyltransferase 1Homo sapiens (human)IC50 (µMol)510.00000.25003.61679.4000AID280501
Carbonic anhydrase 14Homo sapiens (human)Ki0.77300.00021.50999.9000AID1126904
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki7.21000.00001.34129.9700AID1126899
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Taste receptor type 2 member 31Homo sapiens (human)EC50 (µMol)650.00000.00490.00490.0049AID1618073; AID1619259
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (212)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
response to bacteriumCarbonic anhydrase 3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 3Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 31Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 31Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
in utero embryonic developmentProtein arginine N-methyltransferase 1Homo sapiens (human)
protein methylationProtein arginine N-methyltransferase 1Homo sapiens (human)
DNA damage responseProtein arginine N-methyltransferase 1Homo sapiens (human)
cell surface receptor signaling pathwayProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of cell population proliferationProtein arginine N-methyltransferase 1Homo sapiens (human)
RNA splicingProtein arginine N-methyltransferase 1Homo sapiens (human)
peptidyl-arginine methylationProtein arginine N-methyltransferase 1Homo sapiens (human)
viral protein processingProtein arginine N-methyltransferase 1Homo sapiens (human)
regulation of BMP signaling pathwayProtein arginine N-methyltransferase 1Homo sapiens (human)
neuron projection developmentProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of erythrocyte differentiationProtein arginine N-methyltransferase 1Homo sapiens (human)
regulation of megakaryocyte differentiationProtein arginine N-methyltransferase 1Homo sapiens (human)
negative regulation of megakaryocyte differentiationProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of translationProtein arginine N-methyltransferase 1Homo sapiens (human)
negative regulation of JNK cascadeProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of hemoglobin biosynthetic processProtein arginine N-methyltransferase 1Homo sapiens (human)
cardiac muscle tissue developmentProtein arginine N-methyltransferase 1Homo sapiens (human)
protein homooligomerizationProtein arginine N-methyltransferase 1Homo sapiens (human)
cellular response to methionineProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of p38MAPK cascadeProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of TORC1 signalingProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationProtein arginine N-methyltransferase 1Homo sapiens (human)
chromatin remodelingProtein arginine N-methyltransferase 1Homo sapiens (human)
peptidyl-arginine methylation, to asymmetrical-dimethyl arginineProtein arginine N-methyltransferase 1Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (73)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 3Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Homo sapiens (human)
nickel cation bindingCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 31Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 31Homo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
RNA bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
protein bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
N-methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
protein methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
methyl-CpG bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
protein-arginine N-methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
enzyme bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
protein-arginine omega-N monomethyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
protein-arginine omega-N asymmetric methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
histone methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
identical protein bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
histone H4R3 methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
mitogen-activated protein kinase p38 bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
GATOR1 complex bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
S-adenosyl-L-methionine bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (50)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCarbonic anhydrase 3Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
plasma membraneTaste receptor type 2 member 31Homo sapiens (human)
membraneTaste receptor type 2 member 31Homo sapiens (human)
membraneTaste receptor type 2 member 31Homo sapiens (human)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
lysosomal membraneProtein arginine N-methyltransferase 1Homo sapiens (human)
nucleusProtein arginine N-methyltransferase 1Homo sapiens (human)
nucleoplasmProtein arginine N-methyltransferase 1Homo sapiens (human)
cytoplasmProtein arginine N-methyltransferase 1Homo sapiens (human)
cytosolProtein arginine N-methyltransferase 1Homo sapiens (human)
methylosomeProtein arginine N-methyltransferase 1Homo sapiens (human)
nucleusProtein arginine N-methyltransferase 1Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (273)

Assay IDTitleYearJournalArticle
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1275624Inhibition of human recombinant carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
A novel library of saccharin and acesulfame derivatives as potent and selective inhibitors of carbonic anhydrase IX and XII isoforms.
AID711212Inhibition of recombinant Vibrio cholerae carbonic anhydrase expressed in Escherichia coli (DE3) preincubated for 15 mins by stopped-flow CO2 hydrase assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
DNA cloning, characterization, and inhibition studies of an α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1061067Inhibition of Porphyromonas gingivalis recombinant gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID427123Inhibition of Cryptococcus neoformans recombinant Can2 by stopped-flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID349607Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase 1 encoded by Rv1284 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID587132Inhibition of Leptonychotes weddellii alpha-carbonic anhydrase after 15 mins by CO2 hydrase assay at pH 7.52011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Purification and inhibition studies with anions and sulfonamides of an α-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii.
AID552130Inhibition of Stylophora pistillata carbonic anhydrase by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID1454514Inhibition of human ERG at 11 uM by single shot IonWork assay relative to control2017ACS medicinal chemistry letters, Jun-08, Volume: 8, Issue:6
Saccharin Aza Bioisosteres-Synthesis and Preclinical Property Comparisons.
AID648178Inhibition of human wild type carbonic anhydrase 2 expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Mutation of active site residues Asn67 to Ile, Gln92 to Val and Leu204 to Ser in human carbonic anhydrase II: influences on the catalytic activity and affinity for inhibitors.
AID1454510Fraction unbound in human plasma2017ACS medicinal chemistry letters, Jun-08, Volume: 8, Issue:6
Saccharin Aza Bioisosteres-Synthesis and Preclinical Property Comparisons.
AID1126898Inhibition of human recombinant carbonic anhydrase 5A expressed in Escherichia coli by stopped flow CO2 hydration assay2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1126909Selectivity ratio of Ki for human recombinant carbonic anhydrase 5B to Ki for human recombinant carbonic anhydrase 92014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID321156Inhibition of human recombinant CA1 by CO2 hydration stopped flow assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII.
AID1262263Inhibition of human CA1 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID1472889Inhibition of recombinant human carbonic anhydrase 9 expressed in Escherichia coli L21-GOLD (DE3) incubated for 10 mins prior to testing by stopped-flow CO2 hydration assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
"Seriously Sweet": Acesulfame K Exhibits Selective Inhibition Using Alternative Binding Modes in Carbonic Anhydrase Isoforms.
AID1893121Inhibition of human FBPase in ICR mouse serum starved primary hepatocytes assessed as glucose lowering effect at 50 to 100 uM2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
AID1142838Inhibition of Helicobacter pylori carbonic anhydrase by stopped-flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID665436Anticonvulsant activity against maximal electroshock-induced seizures in Swiss mouse at 300 mg/kg, ip after 4 hrs2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 and brain glutamate receptors.
AID1126905Selectivity ratio of Ki for human recombinant carbonic anhydrase 1 to Ki for human recombinant carbonic anhydrase 92014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID665434Anticonvulsant activity against maximal electroshock-induced seizures in Swiss mouse at 30 mg/kg, ip after 4 hrs2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 and brain glutamate receptors.
AID552128Inhibition of human recombinant CA2 by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID1126903Inhibition of human recombinant carbonic anhydrase 12 expressed in Escherichia coli by stopped flow CO2 hydration assay2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1126906Selectivity ratio of Ki for human recombinant carbonic anhydrase 2 to Ki for human recombinant carbonic anhydrase 92014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID497127Inhibition of wild type human recombinant carbonic anhydrase 1 expressed in Escherichia coli BL21 (DE3) after 15 mins by CO2 hydration method2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors.
AID367822Inhibition of Saccharomyces cerevisiae recombinant CA expressed in Escherichia coli by stopped-flow CO2 hydrase assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID1194026Inhibition of recombinant Methanosarcina thermophila gamma-carbonic anhydrase by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID1434430Inhibition of Vibrio cholerae Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID1581515Inhibition of recombinant human carbonic anhydrase 12 incubated for 1 hr prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID1188136Inhibition of Helicobacter pylori Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID552131Inhibition of Stylophora pistillata carbonic anhydrase 2 by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID414956Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration method2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID90374Sensory evaluation was done at a concentration of 330 p.p.m. against other properties.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues with improved organoleptic properties.
AID1061069Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID1275910Inhibition of Vibrio cholerae beta-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1278412Inhibition of Pseudoalteromonas haloplanktis gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1466465Inhibition of recombinant human carbonic anhydrase-2 assessed as reduction in CO2 hydration preincubated for 10 mins measured for 5 to 10 secs by stopped flow assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
N-Substituted and ring opened saccharin derivatives selectively inhibit transmembrane, tumor-associated carbonic anhydrases IX and XII.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1472888Inhibition of recombinant human carbonic anhydrase 2 expressed in Escherichia coli L21-GOLD (DE3) incubated for 10 mins prior to testing by stopped-flow CO2 hydration assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
"Seriously Sweet": Acesulfame K Exhibits Selective Inhibition Using Alternative Binding Modes in Carbonic Anhydrase Isoforms.
AID124219Hypolipidemic activity (9th day serum cholesterol) at 20 mg/kg in CF1 male mice1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Hypolipidemic activity of phthalimide derivatives. 3. A comparison of phthalimide and 1,2-benzisothiazolin-3-one 1,1-dioxide derivatives to phthalimidine and 1,2-benzisothiazoline 1,1-dioxide congeners.
AID1061170Inhibition of Porphyromonas gingivalis gamma-carbonic anhydrase expressed in Escherichia coli preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
AID665435Anticonvulsant activity against maximal electroshock-induced seizures in Swiss mouse at 100 mg/kg, ip after 4 hrs2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 and brain glutamate receptors.
AID497128Inhibition of human recombinant carbonic anhydrase 1 Phe91Asn mutant expressed in Escherichia coli BL21 (DE3) after 15 mins by CO2 hydration method2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors.
AID1194024Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID1126910Selectivity ratio of Ki for human recombinant carbonic anhydrase 6 to Ki for human recombinant carbonic anhydrase 92014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID414955Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration method2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID725955Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID729566Inhibition of human esterase activity of carbonic anhydrase 1 using 4-nitrophenylacetate as substrate after 3 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
Purification and characterization of carbonic anhydrase from sheep kidney and effects of sulfonamides on enzyme activity.
AID1195371Inhibition of Anopheles gambiae carbonic anhydrase pre-incubated for 15 mins by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID414961Inhibition of Mycobacterium tuberculosis H37Rv recombinant beta-carbonic anhydrase 1 expressed in Escherichia coli BL21 by stopped flow CO2 hydration method2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID1287520Inhibition of recombinant Enterobacter sp. B13 beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID743513Inhibition of Helicobacter pylori recombinant alpha carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID1434427Inhibition of recombinant human carbonic anhydrase 1 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID1126915Selectivity ratio of Ki for human recombinant carbonic anhydrase 2 to Ki for human recombinant carbonic anhydrase 122014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID90228Sensory evaluation was done for sweetness at a concentration of 330 p.p.m. against compound potency calculated on weight basis.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues with improved organoleptic properties.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID436564Inhibition of human recombinant CA2 by stopped-flow CO2 assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID1195369Inhibition of human carbonic anhydrase 1 pre-incubated for 15 mins by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID1188137Inhibition of Porphyromonas gingivalis Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID552129Inhibition of human recombinant CA6 by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID1454511Intrinsic clearance in human liver microsomes2017ACS medicinal chemistry letters, Jun-08, Volume: 8, Issue:6
Saccharin Aza Bioisosteres-Synthesis and Preclinical Property Comparisons.
AID1893125Cmax in 12 hrs fasted ICR mouse at 30 mg/kg, ip measured after 24 hrs by LC-MS/MS analysis2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
AID1278411Inhibition of Nostoc commune gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID349608Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 3 expressed in Escherichia coli BL21 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID321159Inhibition of human recombinant CA12 by CO2 hydration stopped flow assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII.
AID280502Inhibition of Aspergillus nidulans recombinant GST-RmtA expressed in BL21 cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations.
AID1466467Inhibition of recombinant human carbonic anhydrase-12 assessed as reduction in CO2 hydration preincubated for 10 mins measured for 5 to 10 secs by stopped flow assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
N-Substituted and ring opened saccharin derivatives selectively inhibit transmembrane, tumor-associated carbonic anhydrases IX and XII.
AID427125Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase method2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID1434429Inhibition of Burkholderia pseudomallei Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID1893113Hypoglycemic activity in ICR mouse assessed as glucose lowering effect at 30 mg/kg, ip measured upto 6 hrs2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
AID1240217Inhibition of human recombinant carbonic anhydrase-2 by stopped flow CO2 hydrase assay method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID1126897Inhibition of human recombinant carbonic anhydrase 4 expressed in Escherichia coli by stopped flow CO2 hydration assay2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1287519Inhibition of Vibrio cholerae beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1126908Selectivity ratio of Ki for human recombinant carbonic anhydrase 5A to Ki for human recombinant carbonic anhydrase 92014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1061066Inhibition of Thalassiosira weissflogii delta carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID1176928Inhibition of BuChE (unknown origin) assessed as reduction in S-butyrylthiocholine chloride hydrolysis at 10 uM after 15 mins by Ellman method2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Sulfonamides as multifunctional agents for Alzheimer's disease.
AID1626171Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions.
AID1076531Inhibition of human carbonic anhydrase 9 by stopped-flow CO2 hydrase assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Design, synthesis and evaluation of N-substituted saccharin derivatives as selective inhibitors of tumor-associated carbonic anhydrase XII.
AID367820Inhibition of human recombinant CA1 by stopped-flow CO2 hydrase assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID1278410Inhibition of Porphyromonas gingivalis gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1188135Inhibition of human recombinant Carbonic anhydrase 2 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID1126904Inhibition of human recombinant carbonic anhydrase 14 expressed in Escherichia coli by stopped flow CO2 hydration assay2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1268963Inhibition of recombinant human carbonic anhydrase-2 by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID1126900Inhibition of human recombinant carbonic anhydrase 6 expressed in Escherichia coli by stopped flow CO2 hydration assay2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID665432Anticonvulsant activity against maximal electroshock-induced seizures in Swiss mouse at 30 mg/kg, ip after 0.5 hrs2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 and brain glutamate receptors.
AID743515Inhibition of human recombinant carbonic anhydrase 1 preincubated for 15 mins by CO2 hydration stopped-flow assay2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID321157Inhibition of human recombinant CA2 by CO2 hydration stopped flow assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII.
AID1194027Inhibition of recombinant Porphyromonas gingivalis gamma-carbonic anhydrase by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID1454512Apparent permeability of the compound across apical side to basolateral side in human Caco2 cells2017ACS medicinal chemistry letters, Jun-08, Volume: 8, Issue:6
Saccharin Aza Bioisosteres-Synthesis and Preclinical Property Comparisons.
AID1076532Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Design, synthesis and evaluation of N-substituted saccharin derivatives as selective inhibitors of tumor-associated carbonic anhydrase XII.
AID711214Inhibition of human recombinant carbonic anhydrase 1 preincubated for 15 mins by stopped-flow CO2 hydrase assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
DNA cloning, characterization, and inhibition studies of an α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID648181Inhibition of human wild type carbonic anhydrase 2 Leu204Ser mutant expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Mutation of active site residues Asn67 to Ile, Gln92 to Val and Leu204 to Ser in human carbonic anhydrase II: influences on the catalytic activity and affinity for inhibitors.
AID1626172Inhibition of human carbonic anhydrase 7 preincubated for 15 mins by stopped flow CO2 hydration assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions.
AID1472890Inhibition of recombinant human carbonic anhydrase 12 expressed in Escherichia coli L21-GOLD (DE3) incubated for 10 mins prior to testing by stopped-flow CO2 hydration assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
"Seriously Sweet": Acesulfame K Exhibits Selective Inhibition Using Alternative Binding Modes in Carbonic Anhydrase Isoforms.
AID1142833Inhibition of human carbonic anhydrase-1 by stopped-flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID644379Inhibition of GST-tagged astrosclera willeyana Astrosclerin-3 expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID1188134Inhibition of human recombinant Carbonic anhydrase 1 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID711213Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped-flow CO2 hydrase assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
DNA cloning, characterization, and inhibition studies of an α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1126895Inhibition of human recombinant carbonic anhydrase 1 expressed in Escherichia coli by stopped flow CO2 hydration assay2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1275626Inhibition of human recombinant carbonic anhydrase 9 preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
A novel library of saccharin and acesulfame derivatives as potent and selective inhibitors of carbonic anhydrase IX and XII isoforms.
AID587131Inhibition of human carbonic anhydrase 2 after 15 mins by CO2 hydrase assay at pH 7.52011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Purification and inhibition studies with anions and sulfonamides of an α-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii.
AID644381Inhibition of human recombinant carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID1275911Inhibition of Vibrio cholerae alpha-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1262264Inhibition of human CA2 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID665431Anticonvulsant activity against maximal electroshock-induced seizures in Swiss mouse at 100 mg/kg, ip after 0.5 hrs2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 and brain glutamate receptors.
AID1454508Distribution coefficient, log D of compound at pH 7.42017ACS medicinal chemistry letters, Jun-08, Volume: 8, Issue:6
Saccharin Aza Bioisosteres-Synthesis and Preclinical Property Comparisons.
AID729564Inhibition of human esterase activity of carbonic anhydrase 9 using 4-nitrophenylacetate as substrate after 3 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
Purification and characterization of carbonic anhydrase from sheep kidney and effects of sulfonamides on enzyme activity.
AID1726079Inhibition of Vibrio cholerae beta carbonic anhydrase pre-incubated for 15 mins prior to testing by phenol red-based stopped-flow CO2 hydration assay2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
In Silico-Guided Identification of New Potent Inhibitors of Carbonic Anhydrases Expressed in
AID1142834Inhibition of human carbonic anhydrase-2 by stopped-flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID665433Anticonvulsant activity against maximal electroshock-induced seizures in Swiss mouse at 300 mg/kg, ip after 0.5 hrs2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 and brain glutamate receptors.
AID1356351Binding affinity to carbonic anhydrase 9 (unknown origin) expressed in Escherichia coli BL21 (DE3)2018ACS medicinal chemistry letters, Jul-12, Volume: 9, Issue:7
Sweet Binders: Carbonic Anhydrase IX in Complex with Sucralose.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1142836Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-1 assessed as CO2 hydrase activity by stopped-flow assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID612726Inhibition of human recombinant carbonic anhydrase 2 at pH 7.5 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID90090Sensory evaluation was done for sweetness at a concentration of 330 p.p.m. against compound potency calculated on a molar basis. 1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues with improved organoleptic properties.
AID648180Inhibition of human wild type carbonic anhydrase 2 Gln92Val mutant expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Mutation of active site residues Asn67 to Ile, Gln92 to Val and Leu204 to Ser in human carbonic anhydrase II: influences on the catalytic activity and affinity for inhibitors.
AID1356350Binding affinity to carbonic anhydrase 2 (unknown origin)2018ACS medicinal chemistry letters, Jul-12, Volume: 9, Issue:7
Sweet Binders: Carbonic Anhydrase IX in Complex with Sucralose.
AID124218Hypolipidemic activity (16th day serum cholesterol) at 20 mg/kg in CF1 male mice1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Hypolipidemic activity of phthalimide derivatives. 3. A comparison of phthalimide and 1,2-benzisothiazolin-3-one 1,1-dioxide derivatives to phthalimidine and 1,2-benzisothiazoline 1,1-dioxide congeners.
AID1626170Inhibition of human carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions.
AID89766Sensory evaluation was done for sweetness at a concentration of 330 p.p.m. against sample intensity relative to 10% sucrose.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues with improved organoleptic properties.
AID1275625Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
A novel library of saccharin and acesulfame derivatives as potent and selective inhibitors of carbonic anhydrase IX and XII isoforms.
AID1472887Inhibition of recombinant human carbonic anhydrase 1 expressed in Escherichia coli L21-GOLD (DE3) incubated for 10 mins prior to testing by stopped-flow CO2 hydration assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
"Seriously Sweet": Acesulfame K Exhibits Selective Inhibition Using Alternative Binding Modes in Carbonic Anhydrase Isoforms.
AID1268964Inhibition of recombinant Sulfurihydrogenibium yellowstonense YO3AOP1 carbonic anhydrase by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID1278409Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by CO2 hydrase stopped flow assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1076530Inhibition of human carbonic anhydrase 12 by stopped-flow CO2 hydrase assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Design, synthesis and evaluation of N-substituted saccharin derivatives as selective inhibitors of tumor-associated carbonic anhydrase XII.
AID1278413Inhibition of recombinant Colwellia psychrerythraea gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1142837Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-2 assessed as CO2 hydrase activity by stopped-flow assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID1195370Inhibition of human carbonic anhydrase 2 pre-incubated for 15 mins by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID1194028Inhibition of recombinant Nostoc commune gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID1188138Inhibition of Porphyromonas gingivalis Gamma-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID665437Neurotoxicity against Swiss mouse at 30 to 300 mg/kg, ip after 4 hrs by rotarod ataxia test2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 and brain glutamate receptors.
AID729565Inhibition of human esterase activity of carbonic anhydrase 2 using 4-nitrophenylacetate as substrate after 3 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
Purification and characterization of carbonic anhydrase from sheep kidney and effects of sulfonamides on enzyme activity.
AID1893124Tmax in 12 hrs fasted ICR mouse at 30 mg/kg, ip measured after 24 hrs by LC-MS/MS analysis2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
AID778725Inhibition of recombinant Leishmania donovani chagasi beta-carbonic anhydrase expressed in baculovirus infected insect Sf9 cells incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1893123Elimination half life in 12 hrs fasted ICR mouse at 30 mg/kg, ip measured after 24 hrs by LC-MS/MS analysis2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
AID1126902Inhibition of human recombinant carbonic anhydrase 9 expressed in Escherichia coli by stopped flow CO2 hydration assay2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID427122Inhibition of Candida albicans recombinant Nce103 by stopped-flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID1454509Solubility of compound in DMSO2017ACS medicinal chemistry letters, Jun-08, Volume: 8, Issue:6
Saccharin Aza Bioisosteres-Synthesis and Preclinical Property Comparisons.
AID427124Inhibition of Helicobacter pylori beta-carbonic anhydrase by stopped-flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID1262267Inhibition of Chionodraco hamatus alphaCA incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID1240216Inhibition of Methanosarcina thermophila recombinant gamma carbonic anhydrase by stopped flow CO2 hydrase assay method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID725956Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID1466466Inhibition of recombinant human carbonic anhydrase-9 assessed as reduction in CO2 hydration preincubated for 10 mins measured for 5 to 10 secs by stopped flow assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
N-Substituted and ring opened saccharin derivatives selectively inhibit transmembrane, tumor-associated carbonic anhydrases IX and XII.
AID1581513Inhibition of recombinant human carbonic anhydrase 7 incubated for 1 hr prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID1126907Selectivity ratio of Ki for human recombinant carbonic anhydrase 4 to Ki for human recombinant carbonic anhydrase 92014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1581512Inhibition of recombinant human carbonic anhydrase 4 incubated for 1 hr prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID437750Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 2 encoded by RV3588c by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
AID497130Selectivity ratio of Ki for wild type human recombinant carbonic anhydrase 1 to Ki for human recombinant carbonic anhydrase 1 Phe91Asn mutant2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1581511Inhibition of recombinant human carbonic anhydrase 2 incubated for 1 hr prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID1061068Inhibition of Leishmania donovani chagasi recombinant beta-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID437749Inhibition of human recombinant CA2 by stopped-flow hydration assay2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
AID90375Sensory evaluation was done at a concentration of 330 p.p.m. against property of bitterness.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues with improved organoleptic properties.
AID280501Inhibition of human recombinant GST-PRMT1 expressed in BL21 cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1126912Selectivity ratio of Ki for human recombinant carbonic anhydrase 12 to Ki for human recombinant carbonic anhydrase 92014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1126913Selectivity ratio of Ki for human recombinant carbonic anhydrase 14 to Ki for human recombinant carbonic anhydrase 92014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID436565Inhibition of cloned Stylophora pistillata alpha-CA expressed in human HEK293 cells by stopped-flow CO2 assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID1126901Inhibition of human recombinant carbonic anhydrase 7 expressed in Escherichia coli by stopped flow CO2 hydration assay2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1275913Inhibition of human Carbonic anhydrase1 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1126896Inhibition of human recombinant carbonic anhydrase 2 expressed in Escherichia coli by stopped flow CO2 hydration assay2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1626173Inhibition of human carbonic anhydrase 9 catalytic site preincubated for 15 mins by stopped flow CO2 hydration assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions.
AID1287517Inhibition of human carbonic anhydrase 1 incubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID1204106Inhibition of recombinant Streptococcus mutans UA159 beta-carbonic anhydrase expressed in Escherichia coli Arctic cells preincubated for 15 mins by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Sulfonamide inhibition study of the β-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans.
AID1434428Inhibition of human carbonic anhydrase 2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID1061169Inhibition of recombinant Methanosarcina thermophila gamma-CA CAM by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID729567Inhibition of sheep kidney esterase activity of carbonic anhydrase using 4-nitrophenylacetate as substrate after 3 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
Purification and characterization of carbonic anhydrase from sheep kidney and effects of sulfonamides on enzyme activity.
AID367821Inhibition of human recombinant CA2 by stopped-flow CO2 hydrase assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID90376Sensory evaluation was done at a concentration of 330 p.p.m. against property of sweetness.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues with improved organoleptic properties.
AID301578Inhibition of human recombinant CA 3 assessed as CO2 hydration by stopped flow kinetic assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.
AID1262266Inhibition of weddell seal alphaCA incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID124217Hypolipidemic activity (14th day serum triglyceride) at 20 mg/kg in CF1 male mice1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Hypolipidemic activity of phthalimide derivatives. 3. A comparison of phthalimide and 1,2-benzisothiazolin-3-one 1,1-dioxide derivatives to phthalimidine and 1,2-benzisothiazoline 1,1-dioxide congeners.
AID1076533Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Design, synthesis and evaluation of N-substituted saccharin derivatives as selective inhibitors of tumor-associated carbonic anhydrase XII.
AID1194025Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID1581514Inhibition of recombinant human carbonic anhydrase 9 incubated for 1 hr prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID349605Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID612725Inhibition of human recombinant carbonic anhydrase 1 at pH 7.5 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID1291363Inhibition of recombinant Vibrio cholerae gamma-carbonic anhydrase preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Comparison of the sulfonamide inhibition profiles of the α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID648179Inhibition of human wild type carbonic anhydrase 2 Asn67Ile mutant expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Mutation of active site residues Asn67 to Ile, Gln92 to Val and Leu204 to Ser in human carbonic anhydrase II: influences on the catalytic activity and affinity for inhibitors.
AID349606Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID644380Inhibition of human recombinant carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID612732Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 2 at pH 8.3 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID1581510Inhibition of recombinant human carbonic anhydrase 1 incubated for 1 hr prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay
AID743512Inhibition of Sulfurihydrogenibium yellowstonense YO3AOP1 recombinant carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID183498Antiinflammatory activity of compound expressed as percentage inhibition of carrageenan edema 4 hr after an oral dose of 10 mg/kg; Not available1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Synthesis and antiinflammatory activity of metabolites of piroxicam.
AID497129Inhibition of human recombinant carbonic anhydrase 2 after 15 mins by CO2 hydration method2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors.
AID1287518Inhibition of human carbonic anhydrase 2 incubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID612731Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 1 at pH 8.3 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1268962Inhibition of recombinant human carbonic anhydrase-1 by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID743514Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by CO2 hydration stopped-flow assay2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID1240215Inhibition of Pseudoalteromonas haloplanktis gamma carbonic anhydrase by CO2 hydration assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID726232Inhibition of Trypanosoma cruzi CL Brener recombinant alpha-carbonic anhydrase expressed in insect Sf9 cell Baculovirus system by stopped flow CO2 hydration assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID1275627Inhibition of human recombinant carbonic anhydrase 12 preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
A novel library of saccharin and acesulfame derivatives as potent and selective inhibitors of carbonic anhydrase IX and XII isoforms.
AID552127Inhibition of human recombinant CA1 by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID1176919Stimulation of Amyloid beta (1 to 40) (unknown origin) fibril formation at Abeta:compound ratio of 1:10 after 4 days by Thioflavin-T fluorescence assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Sulfonamides as multifunctional agents for Alzheimer's disease.
AID1268965Inhibition of recombinant Thiomicrospira crunogena XCL-2 carbonic anhydrase by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID587130Inhibition of human carbonic anhydrase 1 after 15 mins by CO2 hydrase assay at pH 7.52011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Purification and inhibition studies with anions and sulfonamides of an α-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii.
AID1893126AUCt in 12 hrs fasted ICR mouse at 30 mg/kg, ip measured after 24 hrs by LC-MS/MS analysis2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
AID1240214Inhibition of Nostoc commune gamma carbonic anhydrase by CO2 hydration assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID1454513Dissociation constant, pKa of the compound by potentiometric titretion method2017ACS medicinal chemistry letters, Jun-08, Volume: 8, Issue:6
Saccharin Aza Bioisosteres-Synthesis and Preclinical Property Comparisons.
AID1893128Drug uptake in 12 hrs fasted ICR mouse assessed as plasma concentration at 30 mg/kg, ip measured after 0.25 hrs in presence of compound by LC-MS/MS analysis2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
AID1126894Dissociation constant, pKa of the compound2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1126899Inhibition of human recombinant carbonic anhydrase 5B expressed in Escherichia coli by stopped flow CO2 hydration assay2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1466464Inhibition of recombinant human carbonic anhydrase-1 assessed as reduction in CO2 hydration preincubated for 10 mins measured for 5 to 10 secs by stopped flow assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
N-Substituted and ring opened saccharin derivatives selectively inhibit transmembrane, tumor-associated carbonic anhydrases IX and XII.
AID1176929Inhibition of BuChE (unknown origin) assessed as reduction in S-butyrylthiocholine chloride hydrolysis after 15 mins by Ellman method2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Sulfonamides as multifunctional agents for Alzheimer's disease.
AID436563Inhibition of human recombinant CA1 by stopped-flow CO2 assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID183500Antiinflammatory activity of compound expressed as percentage inhibition of carrageenan edema 4 hr after an oral dose of 33 mg/kg.1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Synthesis and antiinflammatory activity of metabolites of piroxicam.
AID1626174Inhibition of human carbonic anhydrase 12 preincubated for 15 mins by stopped flow CO2 hydration assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions.
AID321158Inhibition of human recombinant CA9 by CO2 hydration stopped flow assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1126911Selectivity ratio of Ki for human recombinant carbonic anhydrase 7 to Ki for human recombinant carbonic anhydrase 92014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID1176923Inhibition of Amyloid beta (1 to 42) (unknown origin) oligomer assembly at Abeta:compound ratio of 0.0002 after 30 mins by single-site ELISA assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Sulfonamides as multifunctional agents for Alzheimer's disease.
AID1275912Inhibition of human Carbonic anhydrase2 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1126914Selectivity ratio of Ki for human recombinant carbonic anhydrase 1 to Ki for human recombinant carbonic anhydrase 122014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID1798982CA Inhibition Assay from Article 10.1021/jm9003126: \\Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.\\2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID1799266CA Inhibition Assay from Article 10.1016/j.bmc.2009.05.002: \\Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.\\2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID1798985CA Inhibition Assay from Article 10.1021/jm9000488: \\Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.\\2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,014)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901184 (39.28)18.7374
1990's443 (14.70)18.2507
2000's516 (17.12)29.6817
2010's684 (22.69)24.3611
2020's187 (6.20)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 88.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index88.23 (24.57)
Research Supply Index8.09 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index170.08 (26.88)
Search Engine Supply Index2.09 (0.95)

This Compound (88.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials76 (2.39%)5.53%
Reviews114 (3.58%)6.00%
Case Studies7 (0.22%)4.05%
Observational1 (0.03%)0.25%
Other2,985 (93.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]